AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21292168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg twice daily
Number of subjects: 485
Study 21292168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 21292168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan (both doses)
Number of subjects: 485
Study 19404071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 140
Study 19404071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure
Number of subjects: 140
Study 19404071 — intervention group
Group type: COMPARATOR
Intervention: Both
Number of subjects: 140
Study 17942736 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (allopregnanolone)
Number of subjects: 0
Study 14736307 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of implausible alternatives (duds)
Number of subjects: 0
Study 14736307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnumeric likelihood measures and betting measures
Number of subjects: 0
Study 14736307 — intervention group
Group type: COMPARATOR
Intervention: Numeric likelihood measures
Number of subjects: 0
Study 14736307 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study 11314848 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised feedback
Number of subjects: 801
Study 11314848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personalised feedback)
Number of subjects: 801
Study 9427984 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml mitomycin-C
Number of subjects: 30
Study 9427984 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/ml mitomycin-C
Number of subjects: 30
Study 8490542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (caloric restriction adapted to personal needs and behavior)
Number of subjects: 102
Study 8490542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 3098341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg transdermal oestradiol daily
Number of subjects: 3
Study 3098341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg transdermal oestradiol daily
Number of subjects: 3
Study 3098341 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg transdermal oestradiol daily
Number of subjects: 3
Study 30526778 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal group
Number of subjects: 238
Study 30526778 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menopausal group
Number of subjects: 238
Study 28186933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice Decision Aid
Number of subjects: 204
Study 28186933 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 204
Study 25143179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatology consultation (treatment group)
Number of subjects: 29
Study 25143179 — intervention group
Group type: COMPARATOR
Intervention: PCP management (control group)
Number of subjects: 29
Study 22422031 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (25G vitrectomy and internal limiting membrane peeling with blue dye staining)
Number of subjects: 76
Study 22422031 — intervention group
Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 76
Study 22422031 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (in presence of VPA)
Number of subjects: 76
Study 22422031 — intervention group
Group type: COMPARATOR
Intervention: Control (in presence of VPA)
Number of subjects: 76
Study 22422031 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intra-retinal cysts
Number of subjects: 76
Study 19947131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oraqix
Number of subjects: 45
Study 19947131 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine
Number of subjects: 45
Study 17186295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (LFA)
Number of subjects: 9
Study 17186295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 9
Study 17186295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (LFA and CON)
Number of subjects: 9
Study 15248230 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 15
Study 15248230 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 15
Study 15248230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (combined etanercept and infliximab)
Number of subjects: 15
Study 15248230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 15
Study 15248230 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (interrupted therapy)
Number of subjects: 15
Study 12508476 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem 300 mg 3 times daily
Number of subjects: 60
Study 12508476 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 100 mg 3 times daily
Number of subjects: 60
Study 8611664 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 277
Study 8611664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 2680990 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg b.i.d. for three days
Number of subjects: 10
Study 2680990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for three days
Number of subjects: 10
Study 2680990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 1092515 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1,600 mg, 240 mg, and 600 mg)
Number of subjects: 7
Study 1092515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31481062 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-group treatment focusing on evidence-based parenting practices
Number of subjects: 130
Study 31481062 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment focusing on lifestyle changes
Number of subjects: 130
Study 31481062 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline picky eating measured with the CEBQ
Number of subjects: 130
Study 31481062 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degree of picky eating at baseline (measured with the CEBQ)
Number of subjects: 130
Study 31481062 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBQ and LBC measurements of picky eating
Number of subjects: 130
Study 28436539 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective screening using demographic characteristics
Number of subjects: 222
Study 28436539 — intervention group
Group type: COMPARATOR
Intervention: Selective screening using behavioral indicators
Number of subjects: 222
Study 28436539 — intervention group
Group type: COMPARATOR
Intervention: Random selective screening
Number of subjects: 222
Study 25841133 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 IU heparin
Number of subjects: 459
Study 25841133 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU heparin
Number of subjects: 459
Study 23521323 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0
Study 23521323 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 21807616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) for 10 minutes
Number of subjects: 0
Study 21807616 — intervention group
Group type: COMPARATOR
Intervention: Transcranial static magnetic field stimulation (tSMS)
Number of subjects: 0
Study 19468742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at 20 HZ for 60 minutes
Number of subjects: 20
Study 19468742 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study 16643234 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIH block at 1 cm inferio‐medial to the anterior superior iliac spine (ASIS) with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 132
Study 16643234 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIH block at 1-2 cm medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 132
Study 16643234 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIH block at 2 cm superio‐medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 132
Study 16643234 — intervention group
Group type: COMPARATOR
Intervention: No nerve block (control group)
Number of subjects: 132
Study 14988445 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quercetin onions
Number of subjects: 8
Study 14988445 — intervention group
Group type: COMPARATOR
Intervention: Low-quercetin onions
Number of subjects: 8
Study 11533266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (20% isoenergetic replacement with pecans)
Number of subjects: 23
Study 11533266 — intervention group
Group type: COMPARATOR
Intervention: Step I diet
Number of subjects: 23
Study 9663365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg plus Beano
Number of subjects: 37
Study 9663365 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 100 mg
Number of subjects: 37
Study 7988249 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 172
Study 7988249 — intervention group
Group type: COMPARATOR
Intervention: Postoperative thoracic irradiation alone
Number of subjects: 172
Study 7988249 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy
Number of subjects: 172
Study 7988249 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire study population
Number of subjects: 172
Study 3385548 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: meperidine, promethazine, and chlorpromazine intramuscular
Number of subjects: 58
Study 3385548 — intervention group
Group type: COMPARATOR
Intervention: Group I: meperidine intramuscular
Number of subjects: 58
Study 3385548 — intervention group
Group type: COMPARATOR
Intervention: Group II: atropine intramuscular and diazepam intravenous
Number of subjects: 58
Study 30195894 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surface Goldmann applanation tonometer (GAT) prism
Number of subjects: 173
Study 30195894 — intervention group
Group type: COMPARATOR
Intervention: Standard Goldmann applanation tonometer (GAT) prism
Number of subjects: 173
Study 28031374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention package (interpersonal counseling on IYCF, mass media campaign, community mobilization)
Number of subjects: 4000
Study 28031374 — intervention group
Group type: COMPARATOR
Intervention: Usual nutrition counseling and mass media campaign (nonintensive)
Number of subjects: 4000
Study 26249206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EXE, n = 20)
Number of subjects: 62
Study 26249206 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (INS, n = 21)
Number of subjects: 62
Study 26249206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO, n = 21)
Number of subjects: 62
Study 23823849 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 20
Study 23823849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21445680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive problem-based diabetes self-management training
Number of subjects: 56
Study 21445680 — intervention group
Group type: COMPARATOR
Intervention: Condensed problem-based diabetes self-management training
Number of subjects: 56
Study 18664297 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline gestational diabetes mellitus (BGDM)
Number of subjects: 0
Study 18664297 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born to BGDM mothers
Number of subjects: 0
Study 17249520 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril
Number of subjects: 70
Study 17249520 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 70
Study 17249520 — intervention group
Group type: COMPARATOR
Intervention: Control Hypertensives
Number of subjects: 70
Study 17249520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.3 mg)
Number of subjects: 70
Study 12601517 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 1235
Study 12601517 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine IR 2 mg twice daily
Number of subjects: 1235
Study 12601517 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1235
Study 11808059 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed extract
Number of subjects: 19
Study 11808059 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethyl cellulose preparation (Salinum and MAS‐84)
Number of subjects: 19
Study 9316004 — intervention group
Group type: EXPERIMENTAL
Intervention: New combination chemotherapy regimen incorporating a new agent
Number of subjects: 673
Study 9316004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality adjustment
Number of subjects: 673
Study 9316004 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope analysis (SA) and area under the curve (AUC) analyses
Number of subjects: 673
Study 9316004 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent evaluations of QL
Number of subjects: 673
Study 9316004 — intervention group
Group type: EXPERIMENTAL
Intervention: Following all patients until death
Number of subjects: 673
Study 8175595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g NaHCO3/kg body wt (alkalosis)
Number of subjects: 10
Study 8175595 — intervention group
Group type: COMPARATOR
Intervention: 0.04 g NaCl/kg body wt (control)
Number of subjects: 10
Study 3308368 — intervention group
Group type: EXPERIMENTAL
Intervention: Milligan hemorrhoidectomy combined with anal dilatation
Number of subjects: 40
Study 3308368 — intervention group
Group type: COMPARATOR
Intervention: Hemorrhoidectomy only
Number of subjects: 40
Study 28883098 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based estimation (insertion depth (cm) = weight (kg) +6)
Number of subjects: 136
Study 28883098 — intervention group
Group type: COMPARATOR
Intervention: Vocal cord guide
Number of subjects: 136
Study 26628386 — intervention group
Group type: EXPERIMENTAL
Intervention: Original 15-item NIHSS
Number of subjects: 0
Study 26628386 — intervention group
Group type: COMPARATOR
Intervention: Shortened versions of NIHSS (11, 8, and 5 items)
Number of subjects: 0
Study 26580881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed roe cream (Group 1, n=19)
Number of subjects: 75
Study 26580881 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Glycolic acid (Group 2, n=17)
Number of subjects: 75
Study 26580881 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Glycolic acid plus 2% citric acid (Group 3, n=16)
Number of subjects: 75
Study 23601499 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (group A, N = 23)
Number of subjects: 46
Study 23601499 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (group B, N = 23)
Number of subjects: 46
Study 23601499 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (group A)
Number of subjects: 46
Study 23601499 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (group B)
Number of subjects: 46
Study 23601499 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 46
Study 20625264 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 50 microg/lipopeptide
Number of subjects: 131
Study 20625264 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 150 microg/lipopeptide
Number of subjects: 131
Study 20625264 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 500 microg/lipopeptide
Number of subjects: 131
Study 20625264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 20625264 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5 (all doses)
Number of subjects: 131
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg once daily
Number of subjects: 124
Study 18664477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (high baseline fibrillatory rate >420 fpm)
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (intermediate baseline fibrillatory rate 360-420 fpm)
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (low baseline fibrillatory rate <360 fpm)
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (on-treatment rate <360 fpm)
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (on-treatment rate >360 fpm)
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan effects on fibrillatory rate
Number of subjects: 124
Study 18664477 — intervention group
Group type: EXPERIMENTAL
Intervention: AF recurrence risk
Number of subjects: 124
Study 16325777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean individuals (BMI=23.2+/‐0.4 kg/m²)
Number of subjects: 12
Study 16325777 — intervention group
Group type: COMPARATOR
Intervention: Obese individuals (BMI=35.0+/‐1.1 kg/m²)
Number of subjects: 12
Study 14570722 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micro g octreotide
Number of subjects: 39
Study 14570722 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micro g octreotide
Number of subjects: 39
Study 14570722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 2 mg/ml (group 1)
Number of subjects: 28
Study 10910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 3 mg/ml (group 2)
Number of subjects: 28
Study 10910488 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine (both groups)
Number of subjects: 28
Study 8757206 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (QID + PRN)
Number of subjects: 17
Study 8757206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PRN)
Number of subjects: 17
Study 1558794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg m‐2) administered via a 10 min i.v. infusion to 8 women (10 kinetics)
Number of subjects: 15
Study 1558794 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone associated with high-dose alkylating agents administered to 7 women (7 kinetics)
Number of subjects: 15
Study 1558794 — intervention group
Group type: COMPARATOR
Intervention: High-dose mitoxantrone
Number of subjects: 15
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SHRZ (streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months)
Number of subjects: 319
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SHRZ (isoniazid, rifampin, and pyrazinamide for 1 month)
Number of subjects: 319
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: 2HRZ (isoniazid, rifampin, and pyrazinamide for 2 months without streptomycin)
Number of subjects: 319
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: H3R3 (3‐times‐weekly isoniazid and rifampin up to 6 months)
Number of subjects: 319
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with drug‐sensitive tubercle bacilli
Number of subjects: 319
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tubercle bacilli resistant to isoniazid, streptomycin, or both
Number of subjects: 319
Study 2862820 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 319
Study 31353272 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative counseling and information sources
Number of subjects: 99
Study 30287676 — intervention group
Group type: COMPARATOR
Intervention: US$0 (control)
Number of subjects: 800
Study 30287676 — intervention group
Group type: EXPERIMENTAL
Intervention: US$1.25
Number of subjects: 800
Study 30287676 — intervention group
Group type: EXPERIMENTAL
Intervention: US$2.50
Number of subjects: 800
Study 30287676 — intervention group
Group type: EXPERIMENTAL
Intervention: US$5.00
Number of subjects: 800
Study 30287676 — intervention group
Group type: EXPERIMENTAL
Intervention: US$10.00
Number of subjects: 800
Study 30287676 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (including control)
Number of subjects: 800
Study 23440660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynara scolymus extract (600 mg/d)
Number of subjects: 55
Study 23440660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23364498 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Intervention Group (LIG) - 90 nursing homes, 3,258 participants
Number of subjects: 6275
Study 23364498 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Intervention Group (SIG) - 85 nursing homes, 3,017 participants
Number of subjects: 6275
Study 23364498 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 6275
Study 20495438 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 0
Study 20495438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18817803 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups that slept between sessions
Number of subjects: 5
Study 18817803 — intervention group
Group type: COMPARATOR
Intervention: Groups that did not sleep between sessions
Number of subjects: 5
Study 15985573 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg T enanthate, weekly intramuscular injections)
Number of subjects: 32
Study 15985573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, weekly injections)
Number of subjects: 32
Study 12974980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion
Number of subjects: 30
Study 12974980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus magnesium infusion
Number of subjects: 30
Study 10389848 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp64Arg variant group (n=23)
Number of subjects: 42
Study 10389848 — intervention group
Group type: COMPARATOR
Intervention: Normal allele group (n=19)
Number of subjects: 42